Head and neck cancer trials in Japan
28 trials · From ClinicalTrials.gov, checked 10 November 2026. Ask the study team whether a trial fits you.
- Phase 1Taking peopleA Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- Where
- Chūōku, Kashiwa, Chiba, Kōtō City, Nagoya
- Age
- 18 years and over
- People
- 460 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT06465069 · EU 2024-512927-36-00 - Phase 3Taking peopleJNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC
- Where
- Bunkyō City, Hiroshima, Kashiwa, Nagoya, Osaka, Osaka Sayama Shi, Sendai, Shimotsuke, Shinjuku, Sunto-gun
- Age
- 60 years and over
- People
- 500 worldwide
- Run by
- Johnson & Johnson Enterprise Innovation Inc.
See details and how to joinNCT04892173 · EU 2024-520386-31-00 - Phase 1/2Taking peopleA Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer
- Where
- Nagoya, Tokyo
- Age
- 18 years and over
- People
- 287 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT06385080 · EU 2023-508418-40-00 - Phase 1Taking peopleA Study of JNJ-90301900 in Combination With Chemoradiation Therapy in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma
- Where
- Hiroshima, Kashiwa, Nagoya, Shizuoka, Tokyo
- Age
- 18 years to 74 years
- People
- 45 worldwide
- Run by
- Johnson & Johnson Enterprise Innovation Inc.
See details and how to joinNCT07219212 · EU 2025-522914-22-00 - Phase 3Taking peopleA Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
- Where
- Hirakata, Kashiwa, Nagoya, Sapporo, Shinjuku, Sunto-gun, Tokyo
- Age
- 18 years and over
- People
- 600 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT07276399 · EU 2025-521917-24-00 - Phase 2/3Taking peopleFORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
- Where
- Kōtoku
- Age
- 18 years and over
- People
- 650 worldwide
- Run by
- Bicara Therapeutics
See details and how to joinNCT06788990 · EU 2024-519654-37-00 - Phase 2Taking peopleA Study to Assess Adverse Events, Change in Disease Activity and Optimal Dose of Intravenous (IV) Telisotuzumab Adizutecan With IV Pembrolizumab for First-Line Treatment of Adult Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
- Where
- Kobe
- Age
- 18 years and over
- People
- 150 worldwide
- Run by
- AbbVie
See details and how to joinNCT07744126 · EU 2025-524179-22-00 - Phase 2Taking peopleA Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- Where
- Hidaka, Kagoshima, Kanagawa, Kashiwa-shi, Matsuyama, Nagaizumi-chō, Nagoya, Osakasayama-Shi, Saitama, Tokyo, Yokohama
- Age
- 18 years and over
- People
- 740 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06172478 · EU 2023-507641-29-00 - Phase 1/2Taking peopleA Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
- Where
- Chuo Ku, Kashiwa, Koto-ku, Matsuyama, Nagaizumi-chō, Nagoya, Ōsaka-sayama, Saitama
- Age
- 18 years and over
- People
- 680 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06330064 · EU 2023-509632-26-00 - Phase 1/2Taking peopleA Study of ASP388B Given by Itself and With Standard Therapies in Participants With Solid Tumors
- Where
- Chuo Ku, Koto-ku
- Age
- 18 years and over
- People
- 392 worldwide
- Run by
- Astellas Pharma Global Development, Inc.
See details and how to joinNCT07730021 · EU 2026-525938-31-00 - Phase 1Taking peopleAnti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
- Where
- Tokyo
- Age
- 18 years and over
- People
- 138 worldwide
- Run by
- EMD Serono Research & Development Institute, Inc.
See details and how to joinNCT07360314 · EU 2025-523232-39-00 - Phase 1/2Taking peopleSMP-3124LP in Adults With Advanced Solid Tumors
- Where
- Kashiwa-shi, Kyoto
- Age
- 18 years and over
- People
- 120 worldwide
- Run by
- Sumitomo Pharma America, Inc.
See details and how to joinNCT06526819 - Phase 1Taking peopleStudy to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400
- Where
- Chuo-Ku, Kashiwa-shi, Koto-ku, Kyoto, Nagoya, Sunto-gun
- Age
- 18 years and over
- People
- 325 worldwide
- Run by
- AbbVie
See details and how to joinNCT06084481 · EU 2023-506227-29-00 - Phase 1/2Taking peopleA Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
- Where
- Chūōku, Kashiwa
- Age
- 18 years and over
- People
- 120 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07115043 - Phase 3Taking peopleA Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy
- Where
- Bunkyō City, Chiba, Chūōku, Fukuoka, Hidaka-shi, Hiroshima, Kashiwa, Kobe, Kōtoku, Kyoto, Nagoya, Niigata, Okayama, Osaka, Osakasayama-shi, Sagamihara-shi, Sapporo, Sendai, Shinjuku-ku, Shiwa-gun, Sunto-gun, Yokohama
- Age
- 18 years to 130 years
- People
- 1,145 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06129864 - Phase 1Taking peopleEvaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
- Where
- Chūōku
- Age
- 18 years and over
- People
- 540 worldwide
- Run by
- SystImmune Inc.
See details and how to joinNCT05983432 - Phase 2Taking peopleStudy of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors
- Where
- Kashiwa, Yokohama
- Age
- 18 years to 64 years
- People
- 257 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06535607 · EU 2025-523947-36-00 - Phase 1Taking peopleA Study to Assess the Adverse Events, Change in Disease Activity, and How Oral ABBV-711 Tablets Move Through the Body as a Monotherapy and in Combination With Intravenously Infused Budigalimab (ABBV-181), in Adults With Advanced Squamous Tumors
- Where
- Hirakata-shi, Kashiwa-shi
- Age
- 18 years and over
- People
- 220 worldwide
- Run by
- AbbVie
See details and how to joinNCT07241039 · EU 2025-521607-48-00 - Phase 1/2Taking peopleA Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
- Where
- Kashiwa
- Age
- 18 years and over
- People
- 1,109 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT04895709 - Phase 1Taking peopleAB122 Platform Study
- Where
- Aichi, Chiba, Ehime, Hokkaido, Kanagawa, Osaka, Shizuoka, Tokyo, Wakayama
- Age
- 18 years and over
- People
- 917
- Run by
- Taiho Pharmaceutical Co., Ltd.
See details and how to joinNCT04999761 - Phase 1Taking peopleA Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
- Where
- Kashiwa, Nagaizumi-chō
- Age
- 18 years and over
- People
- 714 worldwide
- Run by
- Seagen, a wholly owned subsidiary of Pfizer
See details and how to joinNCT05208762 · EU 2023-506604-18-00 - Phase 1/2Taking peopleFirst-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
- Where
- Fukuoka, Hirakata, Kōtō City, Kyoto
- Age
- 18 years and over
- People
- 880 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT05768139 · EU 2023-504807-94-00 - Phase 1Taking peopleStudy to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
- Where
- Chuo-ku, Hirakata-shi, Kashiwa-shi, Kobe, Nagoya, Sunto-gun, Wakayama
- Age
- 18 years and over
- People
- 694 worldwide
- Run by
- AbbVie
See details and how to joinNCT05005403 - Phase 1Taking peopleStudy With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
- Where
- Chuo-ku, Wakayama
- Age
- 18 years and over
- People
- 248 worldwide
- Run by
- Calico Life Sciences LLC
See details and how to joinNCT04777994 · EU 2023-507568-38-00 - Phase 1Taking peopleA Clinical Study of KK2260 in Patients With Advanced or Metastatic Solid Tumors
- Where
- Chuo Ku, Fukuoka, Hiroshima, Kashiwa, Kobe, Koto-ku, Kumamoto, Matsuyama, Nagaizumi-chō, Nagoya, Osaka, Sendai, Shinden, Yokohama
- Age
- 18 years and over
- People
- 189
- Run by
- Kyowa Kirin Co., Ltd.
See details and how to joinNCT06248411